Novartis’ “Living Drugs”: Kymriah, Zolgensma – And Diovan?
Executive Summary
Novartis is pioneering the new “living drugs” model. But its present financial performance benefits from regulatory problems that have beset generic competitors to a franchise written off for dead: the antihypertensive brand Diovan (valsartan).